Vitamin K2 MK-4 vs MK-7: Doses, Absorption and Human Evidence

MK-4 and MK-7 are both forms of vitamin K2. MK-7 generally persists longer in circulation and is convenient for once-daily nutritional formulations. MK-4 has a different distribution and research history, including high-dose treatment regimens.

The better choice depends on the question being asked. Absorption, dose convenience, osteocalcin, bone density and cardiovascular events are different endpoints. A favorable pharmacokinetic result cannot answer all of them.

MK-4 versus MK-7 at a glance

The numbers in “MK-4” and “MK-7” describe chemistry. They do not form a potency scale where seven automatically means stronger than four.

What do human absorption studies show?

A comparison in healthy women found measurable, sustained MK-7 concentrations, while nutritional-dose MK-4 was not detectably increased under the study's assay and sampling conditions.

That result supports a pharmacokinetic distinction. It does not mean MK-4 has no biological activity or that an undetectable concentration under one protocol proves failure in every tissue.

A separate MK-7/K1 comparison also demonstrated longer circulating persistence and sustained carboxylation effects with MK-7. That is relevant to dosing convenience, but is not a direct MK-4-versus-MK-7 clinical-outcome trial.

Half-life, accumulation and tissue claims

MK-7's circulating persistence means repeated doses can produce a steadier exposure. MK-4 may be handled differently in tissues, so a short plasma appearance should not be treated as the whole pharmacology.

Retail explanations sometimes turn this into an absolute claim that one form exclusively serves the brain, arteries or bones. Human outcome evidence is needed to support that level of specificity. A tissue-distribution hypothesis is not a substitute for a clinical comparison.

For most buyers, the practical advantage of sustained exposure is a simpler once-daily formulation. Whether that produces a superior health outcome remains dependent on the relevant trials.

Micrograms versus milligrams: the thousandfold difference

Some MK-4 osteoporosis research uses milligram regimens. Comparing that with a 100- or 120-microgram MK-7 capsule without acknowledging the unit difference creates a misleading impression of equivalent treatment.

Do not replace a prescribed regimen with a retail supplement using a simple conversion. Unit conversion tells you mass, not equivalence of effect.

What the bone studies say

An MK-7 trial at 180 micrograms/day reported less loss at some bone sites in healthy postmenopausal women. Another trial at 375 micrograms/day did not find additional structural benefit beyond calcium and D in women with osteopenia, despite improved carboxylation.

MK-4 findings come from different regimens and populations. Comparing the most favorable MK-4 paper with the most favorable MK-7 paper does not create a randomized head-to-head answer.

The bone-health review explains the difference between markers, density and fractures. That outcome distinction is more useful than picking a form solely from a half-life graphic.

What the cardiovascular studies say

Recent coronary-calcification studies have used MK-7. VitaK-CAC used 360 micrograms/day, while DANCODE tested 720 micrograms with D3 in a severe-calcium population.

Positive progression findings in those settings are relevant to MK-7 research. They do not prove that any microgram amount in a commercial product achieves the same result, nor do they establish universal superiority over MK-4 for cardiovascular events.

Use the arterial-calcification guide for the clinical details rather than treating form choice as a replacement for standard risk management.

All-trans MK-7 and product quality

The geometry of MK-7 matters to product specifications, and all-trans claims are common. However, a front-label phrase should not stand in for verified identity, potency and stability information.

An isomer study examined carboxylative activity of trans and cis MK-7 in a laboratory context. It should be interpreted at that level rather than converted into a head-to-head human fracture or heart-outcome claim.

For product evaluation, ask whether the manufacturer identifies the material, provides relevant specifications and can connect testing to the purchased batch. Avoid a percentage claim whose method or meaning cannot be checked.

Should MK-4 and MK-7 be combined?

There is no established universal need to take both as supplements. A formula containing both may reflect a manufacturer's approach, but additional forms do not automatically establish additional benefit.

The same principle applies to D3 and magnesium additions. Assess each ingredient and its amount. A product can be thoughtfully formulated and still be the wrong dose profile for a particular person.

Safety and medicines

Both forms have vitamin K activity and therefore deserve care with vitamin K antagonist therapy. MK-7's long circulating persistence makes casual start-stop changes especially unhelpful in that setting. The anticoagulation team should manage changes.

People using other anticoagulants should still review the full supplement, although those medicines do not act through the identical vitamin K antagonist mechanism. The safety guide explains the distinction.

How to choose in practice

For a once-daily nutritional product, MK-7 is a practical form with relevant human evidence. For a specific prescribed MK-4 regimen, follow the clinical plan rather than substituting a different form based on marketing.

Our first D3/MK-7/L-threonate combination option for a suitable D3 plan is DoNotAge. We have an affiliate relationship with the brand. The buying guide considers its complete dose profile, while the K2 overview helps decide whether a separate K2 supplement is useful in the first place.

Related guides

• Vitamin D3 and K2: Benefits, Dosage and Taking Them Together

Research and sources

Explore the D3, K2 and magnesium research data center for study summaries, population and formulation details, limitations and original publication links. Source links throughout this guide point to the relevant evidence or official guidance.